A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06004245

Public ClinicalTrials.gov record NCT06004245. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 13, 2026, 6:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, and in combination with bevacizumab or pembrolizumab, in participants with microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) advanced solid tumors. VVD-133214 is an oral drug that acts on a protein called Werner (WRN), which may promote the growth of cancers that are MSI and/or dMMR. By acting on WRN, VVD-133214 may be able to block the growth of these types of cancer.

Study identification

NCT ID: NCT06004245
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Vividion Therapeutics, Inc.; Industry
Enrollment: 280 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 24, 2024
Primary completion: May 30, 2027
Completion: May 30, 2027
Last update posted: Aug 16, 2026

2024 – 2027

United States locations

U.S. sites: 16
U.S. states: 12
U.S. cities: 16

Facility	City	State	ZIP	Site status
University of Arizona Cancer Center	Tucson	Arizona	85719	Not yet recruiting
City of Hope Cancer Center	Duarte	California	91010	Recruiting
City of Hope at Irvine Lennar	Irvine	California	91355	Recruiting
START Los Angeles	Los Angeles	California	90025	Recruiting
Emory University School of Medicine	Atlanta	Georgia	30322	Recruiting
University of Chicago	Chicago	Illinois	60637	Not yet recruiting
Norton Cancer Institute - MDC	Louisville	Kentucky	40202	Recruiting
University of Michigan	Ann Arbor	Michigan	48109	Recruiting
START Midwest	Grand Rapids	Michigan	49546	Recruiting
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	08901	Recruiting
Duke University	Durham	North Carolina	27705	Completed
Oklahoma University Health Sciences Center	Oklahoma City	Oklahoma	73170	Recruiting
SCRI Oncology Partners	Nashville	Tennessee	37203	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
START San Antonio	San Antonio	Texas	78229	Recruiting
START Mountain Region	West Valley City	Utah	84119	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06004245, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 16, 2026 · Synced Sep 13, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06004245 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →